Latin America vary widely, from 20% to 90%. 1, 4, 12, 13 When available, reported time from transplant to CDR ranged from 11 to 23 weeks. 13 Based on Chagas disease prevalence in countries of Latin America and US rates of immigration, an estimated 300 000 individuals with Chagas disease live in the United States. 17 Approximately 20%-30% of chronically infected people will develop Chagas disease complications, such as gastrointestinal or cardiac disease. 18 In endemic areas, Chagas disease is a leading cause of cardiomyopathy and sudden cardiac death. 19, 20 In two small studies in the United States, T. cruzi infections were identified in 13%-19% of Latin American immigrants with non-ischemic cardiomyopathy who resided for at least one year in a country where Chagas disease is endemic. 21, 22 The first step to mitigate the potentially devastating effects of CDR in HT recipients is to screen transplant candidates based on epidemiological risk factors such as birth or residence in Latin America. 14 The benefit of monitoring for CDR after transplantation is well-documented, but there is no consensus or widely recommended standard approach. [23] [24] [25] In Latin America, most approaches rely on the identification of trypomastigotes in endomyocardial biopsy or buffy coat, with treatment following the onset of clinical manifestations of CDR. 4, 12 Some centers in Latin America have begun using polymerase chain reaction (PCR) for monitoring. PCR testing of whole blood may identify parasitemia days to weeks before clinical evidence of reactivation can be detected. 2, 24 However, even when monitoring by PCR is performed, antitrypanosomal treatment often is not initiated until after clinical signs or symptoms develop. 24 The approach proposed in the United States is to monitor by PCR and microscopic examination of blood smears and fresh buffy coat preparations and to treat on the basis of laboratory evidence of CDR, before the onset of symptoms. The proposed schedule for monitoring for CDR is identical to the frequently recommended schedule for monitoring for donor-derived infections after transplantation: weekly testing for months 1-2, biweekly testing for month 3, monthly testing for months 4-6, and additional testing beyond 6 months in the event of an unexplained febrile episode or an increase in immunosuppression. 15, 26 This report describes the experience monitoring HT patients at risk for CDR in the United States from 2012 to 2016 using the recommended monitoring approach. 
| ME THODS

| Chagas disease testing
Serologic testing for Chagas disease at CDC included three tests: MNC, TCZ, and 18S as described by Qvarnstrom et al. 28 From 2014 to 2016, the 18S gene assay was excluded from the multitarget assay because of poor sensitivity. 28 Positive and negative controls were 
| Preemptive monitoring for CDR
As was done previously in an assessment of donor-derived Chagas disease, laboratory monitoring after transplant was categorized by adherence to the recommended schedule. 29 Three criteria were assessed: PCR monitoring initiated within 2 weeks of transplantation, weekly testing performed for the first 2 months after transplantation, and biweekly to monthly testing performed until month 6 or until CDR was identified. We defined adherence to recommended monitoring as "Complete" if all three criteria were met; "Partial" if two of the three criteria were met; and "Incomplete" if only one criterion was met or no testing was performed prior to diagnosis at the time of symptom development in the recipient. 
| RE SULTS
From 2012 to 2016, CDC was notified of 31 heart transplant recipients at risk for CDR. The median age of the transplant recipients was 53 years (range: 31-74 years), and 18 (58%) were male ( Table 1) .
Countries of birth were available for 30 (97%) patients; 47% of these patients were born in El Salvador (n = 14), 23% in Mexico (n = 7), and 13% in Honduras (n = 4) ( Table 1 ). The transplants were performed at hospitals across the United States: California (n = 10), New York Table 2 ). The median time from transplantation to the detection of CDR was shortest for the patients monitored following the recommended schedule: 2 weeks for those with complete monitoring, 46.5 weeks for the patients who were partially monitored, and 8 weeks for the patient who was not monitored. 
| Chagas disease reactivation
| Case Series
| Case 13
The recipient was a 42-year-old Hispanic man from El Salvador, 
| Case 16
The recipient was a 47-year-old man from El Salvador who was diagnosed and treated for CC in 2011 during evaluation for congestive heart failure ( Table 1) 
| Case 17
The recipient was a 54-year-old woman born in Santa Barbara, Honduras, who relocated to an urban area of Honduras at age 18 and immigrated to the United States in 1989 (Table 1) . She devel- 
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